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Abstract
Objective: Immunosuppression is cornerstone treatment of antineutrophil cytoplasmic antibody associated vasculitis
(AAV) but is later complicated by infection, cancer, cardiovascular and chronic kidney disease. Caveolin-1 is an
essential structural protein for small cell membrane invaginations known as caveolae. Its functional role has been
associated with these complications. For the first time, caveolin-1 (CAV1) gene variation is studied in AAV.
Methods: CAV1 single nucleotide polymorphism rs4730751 was analysed in genomic DNA from 187 white patients
with AAV from Birmingham, United Kingdom. The primary outcome measure was the composite endpoint of time to
all-cause mortality or renal replacement therapy. Secondary endpoints included time to all-cause mortality, death
from sepsis or vascular disease, cancer and renal replacement therapy. Validation of results was sought from 589
white AAV patients, from two European cohorts.
Results: The primary outcome occurred in 41.7% of Birmingham patients. In a multivariate model, non-CC genotype
variation at the studied single nucleotide polymorphism was associated with increased risk from: the primary outcome
measure [HR 1.86; 95% CI: 1.14-3.04; p=0.013], all-cause mortality [HR:1.83; 95% CI: 1.02-3.27; p=0.042], death
from infection [HR:3.71; 95% CI: 1.28-10.77; p=0.016], death from vascular disease [HR:3.13; 95% CI: 1.07-9.10;
p=0.037], and cancer [HR:5.55; 95% CI: 1.59-19.31; p=0.007]. In the validation cohort, the primary outcome rate was
far lower (10.4%); no association between genotype and the studied endpoints was evident.
Conclusions: The presence of a CC genotype in Birmingham is associated with protection from adverse outcomes
of immunosuppression treated AAV. Lack of replication in the European cohort may have resulted from low clinical
event rates. These findings are worthy of further study in larger cohorts.
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Introduction
Antineutrophil cytoplasmic antibody (ANCA)-associated
small-vessel vasculitides (AAV) represent a heterogeneous
group of clinical syndromes manifesting in multisystem
disorders. Despite success in improving patient life expectancy,
there remains high mortality at 5 years (28% in one study) and
significant morbidity associated with complications of the
disease and its treatment such as infection, cardiovascular
disease, malignancy and chronic kidney disease [1].
Caveolae are lipid raft plasma cell membrane invaginations
of 50-100nm length and although ubiquitously distributed, are
prominently found on fibroblasts, endothelial and epithelial
cells. Caveolin-1 is an essential protein within caveolae and
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acts as an intracellular signalling pathway chaperone in human
fibrotic, vascular and malignant diseases [2–4]. Caveolin-1 also
affects macrophage-related clearance of infection [5,6].
Thus it is biologically plausible that variation within CAV1, the
gene encoding caveolin-1 may play a role in the complications
of AAV and its treatment. Our group has previously identified
an association between a single nucleotide polymorphism
(SNP) within CAV1 (rs4730751) and renal transplant fibrosis
and vascular disease in two independent kidney transplant
cohorts. Subsequently, Testa et al showed this same SNP was
associated with carotid arterial media thickness in renal
replacement therapy (RRT) patients [7,8].
The purpose of this study was to investigate whether this
CAV1 gene variant was associated with clinical outcome in
AAV. The primary outcome measure was chosen as a
combined end-point of time to all-cause mortality and time to
RRT, as this encompassed the increased risk of death from the
co-morbidities associated with AAV and the progression of
kidney disease (and interstitial fibrosis). Following preliminary
results in an AAV cohort from Birmingham, UK, a combined
replication AAV cohort from Germany and the Netherlands was
studied to validate the findings.
Methods
Ethics Statement
The study was performed in accordance with the principles
expressed in the Declaration of Helsinki. Respective National
Ethics Committee approval was sought from: South
Birmingham Regional Ethics Committee 0723, Ethics
committee of the University of Lübeck AZ-06-087 and the
Maastricht Local Ethics Committee 05-158. Study participants
provided written informed consent and the data were analyzed
anonymously.
Patients
In the UK, 200 patients with AAV presenting to the
nephrology service at Queen Elizabeth Hospital, Birmingham
between 1979 and 2009, in whom genomic DNA had also been
isolated as part of the clinical research program at the centre,
were included. To limit the confounding effect of population
stratification, only white patients (self-reported ethnicity) were
included in the study. Patients were diagnosed as ANCA-
associated vasculitis according to the European Medicines
Agency algorithm, where a patient has a clinical diagnosis of
either granulomatosis with polyangiitis (GPA) or microscopic
polyangiitis (MPA), supported by either a positive ANCA assay
or a diagnostic biopsy, and the absence of an alternative
explanation as previously described [9]. Eight patients
presenting during this period with a clinical diagnosis of
eosinophilic granulomatosis with polyangiitis (EGPA) were not
included as nearly 50% are ANCA-negative and treated in a
different manner [9].
The replication Northern European cohort included patients
from the Vasculitis Centre Luebeck/Bad Bramstedt, Germany
and the Maastricht University Medical Centre+, the
Netherlands. In this cohort genomic DNA was available for 596
white patients with GPA or MPA presenting between 1982 and
2009 to the rheumatology services of the respective centres.
Twenty-seven patients with EGPA were not included.
ANCA testing was performed by indirect
immunofluorescence (Birmingham) and ELISA methods
(Germany and the Netherlands) depending on how the data
was collected historically.
Genotyping
Genotyping and phenotyping of the cohorts were performed
independently across centres. CAV1 SNP rs4730751
genotyping was performed using the same Taqman® assay
(Applied Biosystems, Warrington, UK) [7].
Outcome Measures
The primary outcome measure was a composite of time to
all-cause mortality or time to RRT (either dialysis or kidney
transplantation). Established RRT was considered when the
patient required on-going dialysis beyond 3 months. Patients
who initially were dialysis dependent and/or died prior to 3
months were not considered as established RRT for the
purpose of this analysis. This time period was selected as this
is when the majority of patients recover their renal function
after initial dialysis dependence [10,11].
Secondary outcomes included time to all-cause mortality,
time to RRT, time to death from infection, time to death from a
vascular cause (ischaemic heart disease, heart failure,
abdominal aortic aneurysm or cerebral vascular accident) and
time to cancer development from AAV diagnosis. This data was
retrieved from the prospectively maintained institutional
database, and retrospectively corroborated by examining death
certificate records. Non-melanoma skin cancers were
excluded. In the Northern European cohort, whilst no dates of
cancer onset were available, it was known if cancer had
developed during the follow-up period.
The independent effect of genotype on outcome was
assessed by adjusting for the following relevant clinical and
demographic characteristics: age at diagnosis, gender, type of
ANCA and serum creatinine level at presentation.
Statistical Analysis
Data is shown as median (1st and 3rd quartiles) unless
otherwise indicated. Group comparisons were assessed using
Mann-Whitney U and χ2 testing as appropriate. Cumulative
events were analysed with Kaplan-Meier estimates, with the
log-rank test used for intergroup comparison. Time-to-event
analyses were performed using a Cox proportional hazards
model. Categorical outcome data was analysed by logistic
regression. Genotype distributions were assessed for
concordance with Hardy-Weinberg equilibrium using a χ2
goodness-of-fit test with a type 1 error rate set at 5%. CAV1
gene variation at rs4730751 and other relevant clinical and
demographic characteristics were initially examined in a series
of univariate analyses. Known variables that influence AAV
outcomes as well as genotype were included in multivariate
analysis (i.e. no selection process was used to remove these
variables). In addition, an interaction term “CAV1 genotype x
diagnosis” was analysed to examine a differential effect of
genotype depending on clinical diagnosis. A type 1 error rate of
CAV1 SNP in ANCA-Associated Vasculitis
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5% (p≤0.05) was associated with statistical significance. SPSS
software, version 18 (SPSS Inc., Chicago, Illinois) was used for
analysis.
Results
Birmingham Cohort
In the Birmingham cohort, genomic DNA was successfully
genotyped in 187 (>93%) patients. The CAV1 SNP was within
Hardy-Weinberg equilibrium bounds (p>0.05). Demographics of
this cohort are shown in Table 1. The genotype of the patients
at the studied locus was AA in 12.3% (23/187), AC in 38.5%
(72/187), and CC in 49.2% (92/187). During a median follow-up
of 110 months (interquartile range, 67-166 months), 58 patients
died and 37 patients required RRT. There were 78 (41.7%)
primary composite outcome events. Kaplan-Meier estimate of
the primary combined outcome of time to all-cause
mortality/RRT revealed significant differences between
genotypes at rs4730751 (Figure 1A; p=0.022), with inferior
outcomes in patients with non-CC genotype. Overall primary
outcomes rates were 60.9% (14/23) for patients with genotype
AA, 48.6% (35/72) for AC, and 31.5% (29/92) for CC
genotypes. The Cox model examined patient genotype as non-
CC (i.e. AA and AC combined) genotype versus CC genotype.
A univariate association was found between genotype and time
to all-cause mortality/RRT (non-CC vs. CC hazard ratio [HR]:
1.90; 95% confidence interval [CI], 1.19-3.02; p=0.007). This
effect persisted in the multivariate analysis, where a similar HR
was observed (non-CC vs. CC HR, 1.86; 95% CI, 1.14-3.08;
p=0.013), adjusted for age at diagnosis, gender, type of ANCA
and serum creatinine level at presentation.
Table 1. Demographics for Birmingham and Northern
European cohorts are shown.
Characteristic Birmingham Northern Europe p value
Number of patients 187 589  
Age, years 67 (56-77) 63 (52-71) <0.0011
Age at diagnosis, years 58 (46-68) 54 (42-63) 0.0031
Male (%) 104 (56) 302 (51) 0.3142
Genotype    
AA (%) 23 (12) 30 (5) 0.0012
AC (%) 72 (39) 231 (39) 0.9322
CC (%) 92 (49) 328 (56) 0.1302
Granulomatosis with polyangiitis (%) 110 (59) 531 (90) <0.0012
Microscopic polyangiitis (%) 77 (41) 58 (10) <0.0012
Age at diagnosis, years 58 (46-68) 54 (42-63) 0.0031
Creatinine at presentation, µmol/L 182 (100-385) 90 (90-150) <0.0011
Cytoplasmic (c) ANCA (%) 109 (58) Not measured  
Perinuclear (p) ANCA (%) 71 (38) Not measured  
Proteinase 3 (PR3) (%) Not measured 438 (74)  
Myeloperoxidase (MPO) (%) Not measured 97 (17)  
Negative (%) 7 (4) 54 (9)  
1 Mann-Whitney U test
2 Fisher’s exact test
Secondary Analyses
After adjusting for age at diagnosis, gender, creatinine at
presentation and type of ANCA, non-CC genotyped patients
were at significantly increased risk for time to all-cause
mortality, time to death from infection, time to death from a
cardiovascular cause and time to cancer development from
AAV diagnosis. There was some evidence for an increased risk
of RRT for non-CC genotype, but this did not meet criteria for
statistical significance (Table 2).
Figure 1.  Kaplan-Meier analysis of time to all-cause
mortality and renal replacement therapy in the Birmingham
(A) and Northern European (B) cohort by genotype of
CAV1 SNP rs4730751.  The number of patients at risk at
separate time points is shown by year of follow-up. Graphic
data shown to the last surviving 10% patients. p=0.022 (A) and
p=0.427 (B).
doi: 10.1371/journal.pone.0069022.g001
Table 2. Multivariate regression analysis of genotypes non-
CC vs. CC for CAV1 SNP rs4730751.
Variable HR
95% Confidence
Interval p value
Birmingham Cohort    
Time to All-cause mortality 1.83 1.02-3.27 0.042
Time to Death from Vascular cause 3.13 1.07-9.10 0.037
Time to Death from Infection 3.71 1.28-10.77 0.016
Time to Cancer Development from AAV
diagnosis 5.55 1.59-19.31 0.007
Time to Renal Replacement Therapy 1.79 0.86-3.73 0.119
Northern Europe Cohort    
Time to All-cause mortality 0.90 0.44-1.84 0.764
Time to Death from Vascular cause 1.33 0.27-6.67 0.729
Time to Death from Infection 0.24 0.28-2.00 0.196
Cancer 0.77* 0.28-2.17 0.625
Time to Renal Replacement Therapy 1.37 0.63-2.96 0.427
Times to event endpoint for both cohorts were adjusted for age at diagnosis,
gender, creatinine at presentation and type of ANCA.
* Exact date of cancer onset during follow-up period not available, thus logistic
regression analysis used, expressed as Odds Ratio
CAV1 SNP in ANCA-Associated Vasculitis
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Northern European Cohort
In the Northern European cohort, genomic DNA was
successfully genotyped in 589 (>98%) patients. CAV1 SNP
rs4730751 was within Hardy-Weinberg equilibrium bounds
(p>0.05). As shown in Table 1, there was a significantly lower
AA genotype and higher CC genotype prevalence in Northern
Europe as compared to the Birmingham cohort: AA genotype in
5.1% (30/589); AC genotype in 39.2% (231/589), and CC
genotype in 55.7% (328/589). The Northern European cohort
had over 90% of patients diagnosed with GPA as compared to
fewer than 60% Birmingham. The Northern European cohort
also had significantly lower creatinine values (suggesting a
better kidney function) at presentation.
During a median follow-up of 89 months (interquartile range,
48-132 months), there were 33 deaths and 32 patients who
required RRT. In all, there were 61 (10.4%) primary outcome
events as compared to the 41.7% event rate in Birmingham
described above. No association was seen between genotype
and Kaplan-Meier estimates of time to primary outcome
measure (Figure 1B; p=0.427). Overall primary outcome rates
were 10.9% (2/30) for patients with AA genotype, 12.6%
(29/231) for AC genotype, and 9.1% (30/328) for CC genotype.
The Cox model showed no evidence of association between
genotype and the primary outcome measure (non-CC genotype
vs. CC genotype hazard ratio [HR]: 1.29; 95% confidence
interval [CI], 0.78-2.13; p=0.319).
Secondary Analyses
As shown in Table 2, no evidence for an association
between genotype and any of the studied outcome measures
was evident in the replication cohort.
Interaction between CAV1 genotype and Clinical
Diagnosis
Due to current evidence of GPA and MPA being considered
separate genetic disease entities, we next examined the
influence of genotype for each diagnosis. The primary
methodology for this was to examine a statistical interaction
between CAV1 genotype and diagnosis. In addition we
performed a subgroup analysis for each of time to event
outcome.
For all outcomes, the CC genotype was associated with
lower risk. A significant interaction (last column of Table 3)
between CAV1 genotype and diagnosis was observed only for
the ‘Renal Replacement Therapy’ outcome, whereby the
influence of genotype was greater in patients with GPA.
Although at first sight the results of the subgroup analyses
seem to suggest a difference between diagnostic groups
(second to last column of Table 3), this is likely a result of
numbers in the study. The results of the interaction analyses (a
more robust way of examining this issue) do not point to a
differential effect of genotype between diagnoses.
Discussion
This is the first study to evaluate the role of CAV1 gene
variation in determining clinical outcome in patients with AAV.
In the Birmingham cohort, gene variation at the CAV1 SNP
rs4730751 was associated with the chosen combined primary
end-point of time to all-cause mortality or RRT. In addition,
secondary analyses showed an association between this SNP
and all-cause mortality, death from infection, death from
cardiovascular disease, and the development of cancer from
AAV diagnosis.
These findings are plausible from previous studies in
caveolin-1 biology, specifically with its role in vascular disease,
sepsis, cancer and fibrosis. In particular, Testa et al found
evidence of arterial remodelling was dependent on CAV1 SNP
rs4730751 genotype in patients requiring RRT [8]. Reduced
caveolin-1 expression is also seen in vascular smooth muscle
cells of patients with established atheromatous disease [12].
Cav-1 deletion supressed macrophage phagocytosis with
impaired bacterial clearance in murine models of sepsis,
leading to increased mortality [6,13,14]. Caveolin-1 has also
been widely associated as a prognostic marker in several
cancers. Caveolin-1 down-regulation is found in human
ovarian, lung and breast carcinomas [15]. In systemic sclerosis,
caveolin-1 is thought to be anti-fibrotic by its effect on TGFβ
signalling by receptor degradation [16]; as a model of
accelerated fibrosis, renal allograft failure has been associated
with CAV1 SNP rs4730751 donor genotype [7].
The association between genotype and clinical outcome was
not replicated in the Northern European cohort. There may be
a number of reasons underlying this. The Northern European
cohort appeared to have a lower expected event rate for an
AAV cohort. Flossmann et al studied 535 patients with GPA or
MPA as part of the European Vasculitis Study Group. Over a
median follow-up of 5.2 years, there was a 25% mortality rate,
with 32.3% of deaths from infection, 21.1% of deaths from
Table 3. Cox regression analyses assessing the
association of genotype upon the outcomes when the
cohort is divided into diagnoses and then an assessment of
the significance of interaction to address if the CAV1 SNP
genotype effect varied between diagnoses.
Time to Event Diagnosis
Hazard Ratio
(95% CI)
CC vs. non-
CC P-value
Interaction P-
value
All-cause mortality or
RRT GPA 0.56 (0.36, 0.86)  0.009 0.66
 MPA 0.67 (0.39, 1.15) 0.15  
All-cause mortality GPA 0.74 (0.43, 1.29) 0.29 0.25
 MPA 0.47 (0.25, 0.90) 0.02  
Death from vascular
cause GPA 0.33 (0.11, 1.04) 0.06 0.95
 MPA 0.33 (0.10, 1.06) 0.06  
Death from infection GPA 0.63 (0.24, 1.66) 0.35 0.49
 MPA 0.40 (0.15, 1.09) 0.07  
Cancer *) GPA 0.18 (0.04, 0.82) 0.03 0.62
 MPA 0.11 (0.01, 0.87) 0.04  
Renal Replacement
Therapy GPA 0.39 (0.20, 0.76) 0.006 0.04
 MPA 1.16 (0.54, 2.51) 0.70  
* Analysis performed on Birmingham data only, as time to cancer data was
unavailable for the Northern European cohort.
CAV1 SNP in ANCA-Associated Vasculitis
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cardiovascular cause, and a 9.3% cancer incidence [1].
Outcomes in the Birmingham cohort were similar, as over a
median follow-up of 9.2 years the respective rates were 31.0%,
11.8%, 10.2% and 11.8%. In contrast, in the Northern
European cohort over a median follow-up of 7.4 years, the
respective rates were only 5.6%, 1.2%, 1.0% and 2.9%. The
Northern European cohort was younger than that of
Birmingham, and in particular had better kidney function at
presentation. This likely reflects the “rheumatological” nature of
the Northern European cohort versus the “nephrological”
nature of the Birmingham cohort. Certainly kidney function at
presentation is an important determinant of outcome in AAV,
and this may explain the discrepancy between the cohorts, and
the lack of association in the replication study. In addition, a
difference in proportions of patients with GPA versus MPA was
seen between the cohorts. Interestingly, we found some
evidence that the influence of genotype differed between
diagnoses for the time to requirement of renal replacement
therapy, with a more marked effect in patients with a clinical
diagnosis of GPA. This preliminary observation is relevant in
light of emerging evidence that MPA and GPA are genetically
distinct condition [9]. It should be acknowledged that the study
design did not take in to account the varying
immunosuppression protocols of the differing institutions, nor
the severity of the disease activity. In addition, we acknowledge
the possibility of ascertainment bias with regard to patient
outcomes in this observational study. Finally, the issue of
cryptic population stratification always exists in studies such as
this, although the inclusion of only white patients goes some
way to limit the confounding effect of this.
In summary, this is the first study to describe the association
between CAV1 variation and the outcomes of patients with
ANCA associated vasculitis. This study suggests a relationship
between the CAV1 SNP rs4730751 and complications of AAV
and its treatment, although the effect may be context-specific.
Further investigation in future cohorts is warranted to establish
whether this gene variant is of utility as a prognostic biomarker,
either in isolation, or as part of a genetic biomarker panel.
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